

Oriental Rail Infrastructure Limited (Formerly known as Oriental Veneer Products Limited)

CIN: L35100MH1991PLC060686
 Regd. Office: Survey No. 49, Village Aghai, via Kalyan Railway Station, Thane- 421 601; Tel No.: 022-61389400;
 E-mail: compliance@orientalrail.co.in; Website: www.orientalrail.com

Extract of Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025

(Rs. in Lakhs except EPS)

Sr. No.	Particulars	Quarter ended		Nine months ended		Year ended	
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
1.	Revenue from Operations	16,857.53	13,339.40	15,281.79	41,987.36	46,200.88	60,221.55
2.	Net Profit/ (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	1,831.68	1,423.31	1,025.88	4,085.87	3,240.50	4,440.17
3.	Net Profit/ (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,831.68	1,423.31	1,025.88	4,085.87	3,240.50	4,440.17
4.	Net Profit/ (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,382.46	1,066.57	752.49	3,036.41	2,384.20	2,921.59
5.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and other Comprehensive Income (after Tax)]	1,382.46	1,066.57	752.49	3,036.41	2,384.20	2,921.59
6.	Paid-up Equity share capital	670.59	670.59	645.59	670.59	645.59	645.59
7.	Other equity	-	-	-	-	-	-
8.	Earnings Per Share (Face Value Rs. 1/- each)	2.06	1.59	1.17	4.53	3.69	4.68
	Basic:	2.06	1.59	1.17	4.53	3.69	4.68
	Diluted:	2.06	1.59	1.17	4.53	3.69	4.68

The Financial Results on standalone basis are as under

(Rs. in Lakhs except EPS)

Sr. No.	Particulars	Quarter ended		Nine months ended		Year ended	
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
1.	Revenue from Operations	5,414.38	4,261.17	2,510.43	13,124.52	11,194.60	15,315.84
2.	Net Profit/ (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	718.99	518.37	188.75	1,581.00	960.82	1,440.85
3.	Net Profit/ (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	536.46	387.90	136.84	1,146.98	705.96	1,028.89

Notes:

1. The above financial results have been reviewed by the Audit Committee & approved by the Board of Directors in its meeting held on February 04, 2026.
2. The above is an extract of the detailed format of Unaudited Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results for the quarter and nine months ended December 31, 2025 are available on the Stock Exchange website www.bseindia.com and the website of the Company www.orientalrail.com.
3. The Company mainly operates in one segment namely "Indian Railway Products" and hence segment details are not required to be published.
4. Previous period/year figures have been recast/re-grouped to conform to the current period's/year's presentation

For and on behalf of Board of Director

Oriental Rail Infrastructure Limited

Sd/-


Karim N. Mithiborwala

Managing Director

DIN: 00171326

Place: Mumbai

Date : February 04, 2026

**Global Health Limited**

CIN: L85110DL2004PLC128319

Regd. Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India

Corp. Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana 122001, India

Tel: +91 124 483 4060 | E-mail: compliance@medanta.org | Website: www.medanta.org**EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025**

(₹ in Millions except EPS)

Sl. No.	Particulars	Quarter ended		Nine months period ended		Quarter ended	
		31.12.2025	(Unaudited)	31.12.2025	(Unaudited)	31.12.2024	(Unaudited)
1	Revenue from operations	11,210.47		32,511.06		9,434.36	
2	Net profit for the period (before tax and exceptional items)	1,563.81		5,287.59		1,890.68	
3	Net profit for the period before tax (after exceptional items)	1,197.83		5,277.38		1,890.68	
4	Net profit for the period after tax (after exceptional items)	950.33		4,124.15		1,428.58	
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	956.53		4,123.45		1,457.41	
6	Paid up equity share capital	537.58		537.58		537.17	
7	Reserves (excluding Revaluation Reserve)*						
8	Earnings Per Share (of Rs 2/- each) -						
	Basic:	3.54		15.35		5.32	
	Diluted:	3.54		15.32		5.32	

* Reserves (excluding Revaluation Reserve) as on 31 March 2025 was Rs 33,326.93 Million.

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Millions)

Sl. No.	Particulars	Quarter ended		Nine months period ended		Quarter ended	
		31.12.2025	(Unaudited)	31.12.2025	(Unaudited)	31.12.2024	(Unaudited)
1	Revenue from operations	9,401.65		27,487.49		8,123.67	
2	Net profit for the period (before tax and exceptional items)	1,380.86		4,858.02		1,752.75	
3	Net profit for the period before tax (after exceptional items)	1,028.86		4,861.79		1,752.75	
4	Net profit for the period after tax (after exceptional items)	799.07		3,720.70		1,313.86	
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	803.83		3,719.73		1,339.41	

Notes:

1. These results have been reviewed and recommended by the Audit Committee and accordingly approved by the Board of Directors of the Company at their respective meetings held on 4 February 2026. The result have been subjected to the limited review by the statutory auditors of the Company.
2. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone Quarter/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and also available at the company's website www.medanta.org.

By order of the Board

for Global Health Limited

Sd/-

Dr. Naresh Trehan

Chairman and Managing Director

Place: Gurugram

Date: 4 February 2026

**Aarti Drugs Limited**

Registered Office: Plot No. N-198, MIDC, Tarapur, Village Pamtermbhi, Dist. Palghar - 401 506, Maharashtra

CIN: L37060MH1984PLC055433 Email ID: investorrelations@aaritidrugs.com Website: www.aaritidrugs.com**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025**

(₹ In Lacs except for share data)

PARTICULARS	Standalone						Consolidated	
-------------	------------	--	--	--	--	--	--------------	--